| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Galina Seledtsova | Q70903213 |
| Victor I. Seledtsov | Q72315243 | ||
| Andrey Goncharov | Q86883693 | ||
| P2093 | author name string | A G Goncharov | |
| G V Seledtsova | |||
| V I Seledtsov | |||
| P2860 | cites work | Functional and physical interaction between Bcl-X(L) and a BH3-like domain in Beclin-1 | Q24303558 |
| Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade | Q24535835 | ||
| Pathogen recognition and inflammatory signaling in innate immune defenses | Q24643034 | ||
| Therapeutic cancer vaccines: past, present, and future | Q26863283 | ||
| Immunotherapeutic approach for better management of cancer--role of IL-18 | Q27001053 | ||
| Innate and adaptive immune cells in the tumor microenvironment | Q27008342 | ||
| Cancer immunotherapy | Q27026870 | ||
| Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion | Q28131654 | ||
| Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria | Q28265610 | ||
| TRAM couples endocytosis of Toll-like receptor 4 to the induction of interferon-beta | Q28506630 | ||
| Mouse glucocorticoid-induced tumor necrosis factor receptor ligand is costimulatory for T cells | Q28513895 | ||
| Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants | Q29615635 | ||
| Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab | Q29620596 | ||
| Synergistic enhancement of CD8+ T cell-mediated tumor vaccine efficacy by an anti-transforming growth factor-beta monoclonal antibody | Q33581597 | ||
| Rational combinations of immunotherapeutics that target discrete pathways | Q33606144 | ||
| Tumor immunology and cancer immunotherapy: summary of the 2013 SITC primer | Q33689478 | ||
| Vaccines against human carcinomas: strategies to improve antitumor immune responses | Q33734281 | ||
| Adjuvant IL-7 or IL-15 overcomes immunodominance and improves survival of the CD8+ memory cell pool | Q33736534 | ||
| Chemokines as Cancer Vaccine Adjuvants. | Q33792344 | ||
| NK cell-based immunotherapy for malignant diseases | Q33827433 | ||
| Targeting inhibitory pathways in cancer immunotherapy | Q33950640 | ||
| Immunotherapeutic potential of whole tumour cells. | Q34145714 | ||
| B7-H4, a molecule of the B7 family, negatively regulates T cell immunity | Q34207473 | ||
| Impact of sex steroid ablation on viral, tumour and vaccine responses in aged mice. | Q34374590 | ||
| Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease | Q34499843 | ||
| Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. | Q34504134 | ||
| Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity | Q34505678 | ||
| Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity | Q34554995 | ||
| IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients | Q34657691 | ||
| CTLA-4: new insights into its biological function and use in tumor immunotherapy | Q34711491 | ||
| Therapeutic cancer vaccines: are we there yet? | Q34786691 | ||
| GM-CSF-based cancer vaccines | Q35005952 | ||
| Hydrogen peroxide as second messenger in lymphocyte activation | Q35007083 | ||
| Chemokines: attractive mediators of the immune response | Q35031893 | ||
| Simultaneous blocking of human Toll-like receptors 2 and 4 suppresses myeloid dendritic cell activation induced by Mycobacterium bovis bacillus Calmette-Guérin peptidoglycan | Q35164750 | ||
| Therapeutic effect of MIP-1alpha-recruited dendritic cells on preestablished solid and metastatic tumors | Q39732316 | ||
| Cancer immunotherapy. | Q39958332 | ||
| IL-15-induced human DC efficiently prime melanoma-specific naive CD8+ T cells to differentiate into CTL. | Q40134661 | ||
| A differential-avidity model for T-cell selection | Q40626070 | ||
| Comparative analysis of the in vivo expression of tyrosinase, MART-1/Melan-A, and gp100 in metastatic melanoma lesions: implications for immunotherapy. | Q40870788 | ||
| The expanding universe of T-cell subsets: Th1, Th2 and more. | Q41120396 | ||
| A unique natural human IgG antibody with anti-alpha-galactosyl specificity | Q41878407 | ||
| Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. | Q42829424 | ||
| B cell-regulated immune responses in tumor models and cancer patients | Q42969728 | ||
| The role of NF-kappa B in TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis of melanoma cells | Q43582866 | ||
| The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP. | Q44361998 | ||
| Histamine H2-receptor-mediated regulation of human natural killer cell activity. | Q44735915 | ||
| Uric acid promotes tumor immune rejection | Q45003959 | ||
| Montanide ISA 720 vaccines: quality control of emulsions, stability of formulated antigens, and comparative immunogenicity of vaccine formulations | Q45308673 | ||
| Pulse interleukin-2 with famotidine induces CD56+ lymphocytes in the peripheral blood of patients with metastatic melanoma or kidney cancer. | Q45994549 | ||
| A clinical grade poly I:C-analogue (Ampligen) promotes optimal DC maturation and Th1-type T cell responses of healthy donors and cancer patients in vitro. | Q46269868 | ||
| Immunologic response to primary cryoablation of high-risk prostate cancer | Q46507773 | ||
| Control of dendritic cell maturation and function by triiodothyronine. | Q46908239 | ||
| Chimeric antigen receptor T-cell therapy to target hematologic malignancies | Q50049515 | ||
| Xenovaccinotherapy for colorectal cancer. | Q52576592 | ||
| Phase II trial of B7-1 (CD-86) transduced, cultured autologous tumor cell vaccine plus subcutaneous interleukin-2 for treatment of stage IV renal cell carcinoma | Q58748472 | ||
| Polyriboinosinic polyribocytidylic acid (poly(I:C)) induces stable maturation of functionally active human dendritic cells | Q59394046 | ||
| Significant Antitumor Effects Obtained by Autologous Tumor Cell Vaccine Engineered to Secrete Interleukin (IL)-12 and IL-18 by Means of the EBV/Lipoplex | Q62735878 | ||
| Histamine type-2 receptor antagonist immune modulation. II. Cimetidine and ranitidine increase interleukin-2 production | Q68825802 | ||
| Interaction of the natural anti-Gal antibody with alpha-galactosyl epitopes: a major obstacle for xenotransplantation in humans | Q71604759 | ||
| An 'antigenic ligand competition' model for antigen receptor-mediated lymphocyte selection | Q71706273 | ||
| Successful tumour immunotherapy with cimetidine in mice | Q72458491 | ||
| Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function | Q73121472 | ||
| A possible role of pre-existing IgM/IgG antibodies in determining immune response type | Q73234232 | ||
| Melatonin enhances IL-2, IL-6, and IFN-gamma production by human circulating CD4+ cells: a possible nuclear receptor-mediated mechanism involving T helper type 1 lymphocytes and monocytes | Q73500923 | ||
| Exogenous melatonin: quantitative enhancement in vivo of cells mediating non-specific immunity | Q73539294 | ||
| Serum cytokine levels in response to hepatic cryoablation | Q79548485 | ||
| Xenovaccinotherapy for melanoma | Q79577966 | ||
| Thymosin alpha 1 as an adjunct to influenza vaccination in the elderly: rationale and trial summaries | Q80545654 | ||
| Decitabine up-regulates S100A2 expression and synergizes with IFN-gamma to kill uveal melanoma cells | Q81039017 | ||
| Vitiligo is an independent favourable prognostic factor in stage III and IV metastatic melanoma patients: results from a single-institution hospital-based observational cohort study | Q84270711 | ||
| Identification of immunologic biomarkers associated with clinical response after immune-based therapy for cancer | Q84576498 | ||
| QS-21: a water-soluble triterpene glycoside adjuvant | Q94447746 | ||
| Clinical investigations of Toll-like receptor agonists | Q94701660 | ||
| Beyond cancer vaccines: a reason for future optimism with immunomodulatory therapy | Q35294382 | ||
| Tumor-Associated Carbohydrate Antigens Defining Tumor Malignancy: Basis for Development of Anti-Cancer Vaccines | Q35554103 | ||
| Therapeutic Cancer Vaccines in Prostate Cancer: The Paradox of Improved Survival Without Changes in Time to Progression | Q35584269 | ||
| Tumour suppression induced by the macrophage activating lipopeptide MALP-2 in an ultrasound guided pancreatic carcinoma mouse model | Q35596295 | ||
| Induction of protective cytotoxic T cells to murine cytomegalovirus by using a nonapeptide and a human-compatible adjuvant (Montanide ISA 720). | Q35833323 | ||
| Protein hormones and immunity | Q35847104 | ||
| Effective immunotherapy against cancer: a question of overcoming immune suppression and immune escape? | Q35874966 | ||
| Multiple costimulatory modalities enhance CTL avidity | Q35901490 | ||
| Is secondary lymphoid-organ chemokine (SLC/CCL21) much more than a constitutive chemokine? | Q35907076 | ||
| Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice. | Q36183600 | ||
| Cross-presentation of glycolipid from tumor cells loaded with alpha-galactosylceramide leads to potent and long-lived T cell mediated immunity via dendritic cells | Q36229067 | ||
| Tumour markers: An overview | Q36264719 | ||
| Myeloid derived suppressor cells in human diseases | Q36338349 | ||
| Potent immune response against HIV-1 and protection from virus challenge in hu-PBL-SCID mice immunized with inactivated virus-pulsed dendritic cells generated in the presence of IFN-alpha | Q36371335 | ||
| Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells | Q36375909 | ||
| gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand | Q36401461 | ||
| Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunity | Q36459336 | ||
| The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design | Q36547207 | ||
| Cimetidine modulates the antigen presenting capacity of dendritic cells from colorectal cancer patients | Q36644294 | ||
| Interleukin 21: a cytokine/cytokine receptor system that has come of age | Q36803809 | ||
| Development of TLR9 agonists for cancer therapy | Q36809776 | ||
| Immunomodulatory effects of interferons in malignancies | Q36825411 | ||
| Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer | Q36869774 | ||
| The Yin and Yang of interleukin-21 in allergy, autoimmunity and cancer | Q36897846 | ||
| Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiation | Q36968256 | ||
| Combination of radiofrequency ablation and immunotherapy. | Q36991803 | ||
| Interleukin-21 signaling: functions in cancer and autoimmunity | Q37023090 | ||
| About human tumor antigens to be used in immunotherapy | Q37131634 | ||
| New aspects of NK cell subset identification and inference of NK cells' regulatory capacity by assessing functional and genomic profiles | Q37136148 | ||
| Hyperthermia on immune regulation: a temperature's story | Q37206103 | ||
| Role of toll-like receptors in tissue repair and tumorigenesis | Q37208909 | ||
| The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy | Q37243188 | ||
| Ipilimumab: controversies in its development, utility and autoimmune adverse events | Q37387037 | ||
| Pathogen recognition by innate immunity and its signaling | Q37444445 | ||
| Toll-like receptors as targets in chronic liver diseases | Q37469924 | ||
| Enhancing immune responses to tumor-associated antigens | Q37531720 | ||
| Emerging role of human basophil biology in health and disease | Q37584453 | ||
| Overcoming the hurdles of randomised clinical trials of therapeutic cancer vaccines | Q37736080 | ||
| Anti-inflammatory plant natural products for cancer therapy | Q37739942 | ||
| Adjuvants for cancer vaccines | Q37757731 | ||
| Tumor vaccines and beyond | Q37808467 | ||
| Immunologic biomarkers as correlates of clinical response to cancer immunotherapy | Q37827418 | ||
| Recent developments in cancer vaccines | Q37830226 | ||
| Triggering of toll-like receptor signaling pathways in T cells contributes to the anti-tumor efficacy of T cell responses. | Q37847272 | ||
| TLR based therapeutics | Q37866497 | ||
| Mechanism of T cell exhaustion in a chronic environment | Q37869551 | ||
| Adjuvants for enhancing the immunogenicity of whole tumor cell vaccines. | Q37873932 | ||
| Cancer immunotherapy--revisited | Q37908998 | ||
| Autologous versus allogeneic cell-based vaccines? | Q37939522 | ||
| Development of novel immune interventions for prostate cancer | Q37992735 | ||
| Cancer-testis antigens: the current status on antigen regulation and potential clinical use. | Q37995200 | ||
| Non-steroidal anti-inflammatory drugs, tumour immunity and immunotherapy | Q37997202 | ||
| Immunotherapy: a useful strategy to help combat multidrug resistance | Q38000768 | ||
| Oxidative stress and immunosenescence: therapeutic effects of melatonin | Q38076420 | ||
| Interferon-γ-induced necrosis: an antitumor biotherapeutic perspective | Q38097514 | ||
| Manipulating immune cells for adoptive immunotherapy of cancer | Q38188718 | ||
| TLR Agonists for Cancer Immunotherapy: Tipping the Balance between the Immune Stimulatory and Inhibitory Effects | Q38195599 | ||
| Understanding the biology of antigen cross-presentation for the design of vaccines against cancer | Q38208305 | ||
| Xenogeneic therapeutic cancer vaccines as breakers of immune tolerance for clinical application: to use or not to use? | Q38212485 | ||
| Cimetidine suppresses lung tumor growth in mice through proapoptosis of myeloid-derived suppressor cells | Q39230836 | ||
| Modifying tumor-associated macrophages: An important adjunct to immunotherapy | Q39255924 | ||
| P433 | issue | 4 | |
| P921 | main subject | immunotherapy | Q1427096 |
| P304 | page(s) | 851-869 | |
| P577 | publication date | 2015-01-01 | |
| P1433 | published in | Human Vaccines & Immunotherapeutics | Q21072749 |
| P1476 | title | Clinically feasible approaches to potentiating cancer cell-based immunotherapies | |
| P478 | volume | 11 |
| Q41973429 | A Possible Role for Idiotype/Anti-idiotype B-T Cell Interactions in Maintaining Immune Memory. |
| Q92692036 | Antibodies targeting sialyl Lewis A mediate tumor clearance through distinct effector pathways |
| Q59800898 | Attaining threshold antibody cytotoxicity for selective tumor cell destruction: an opinion article |
| Q89638932 | Cancer/testis antigens expression during cultivation of melanoma and soft tissue sarcoma cells |
| Q51040316 | Differential Role of B Cells and IL-17 Versus IFN-γ During Early and Late Rejection of Pig Islet Xenografts in Mice. |
| Q37709102 | Elevated serum granulocyte-macrophage colony-stimulating factor levels during radiotherapy predict favorable outcomes in lung and esophageal cancer |
| Q26749294 | Endothelial Dysfunction and Inflammation: Immunity in Rheumatoid Arthritis |
| Q37687530 | Immune adjuvant effect of a Toxoplasma gondii profilin-like protein in autologous whole-tumor-cell vaccination in mice. |
| Q93189340 | Immune regulation and anti-cancer activity by lipid inflammatory mediators |
| Q48193685 | Immunomodulation by ionizing radiation-impact for design of radio-immunotherapies and for treatment of inflammatory diseases. |
| Q91525197 | Inflammation induced by incomplete radiofrequency ablation accelerates tumor progression and hinders PD-1 immunotherapy |
| Q64072891 | Magnetic resonance imaging monitoring therapeutic response to dendritic cell vaccine in murine orthotopic pancreatic cancer models |
| Q40256333 | Mesothelin-targeting chimeric antigen receptor-modified T cells by piggyBac transposon system suppress the growth of bile duct carcinoma |
| Q33602583 | Novel role of granulocyte-macrophage colony-stimulating factor: antitumor effects through inhibition of epithelial-to-mesenchymal transition in esophageal cancer |
| Q92627569 | Profiling of Target Molecules for Immunotherapy in Mesenchymal Tumors |
| Q47141906 | Sp17 Protein Expression and Major Histocompatibility Class I and II Epitope Presentation in Diffuse Large B Cell Lymphoma Patients. |
| Q52657140 | Targeting LAG-3 and PD-1 to Enhance T Cell Activation by Antigen-Presenting Cells. |
| Q40202216 | Tumor growth limited to subcutaneous site vs tumor growth in pulmonary site exhibit differential effects on systemic immunities. |
Search more.